1,2-distearoyllecithin has been researched along with carboplatin in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chaudhury, A; Chiu, GN; Das, S; Lee, RF; Ng, WK; Tan, KB; Tan, RB | 1 |
Khemapech, N; Lertkhachonsuk, R; Oranratanaphan, S; Termrungruanglert, W; Vasurattana, A | 1 |
2 other study(ies) available for 1,2-distearoyllecithin and carboplatin
Article | Year |
---|---|
Lyophilization of cholesterol-free PEGylated liposomes and its impact on drug loading by passive equilibration.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Antineoplastic Agents; Carboplatin; Chemistry, Pharmaceutical; Cryoprotective Agents; Drug Compounding; Drug Stability; Freeze Drying; Glucose; Hydrophobic and Hydrophilic Interactions; Kinetics; Lipids; Liposomes; Particle Size; Phosphatidylcholines; Phosphatidylethanolamines; Polyethylene Glycols; Solubility; Sucrose; Technology, Pharmaceutical; Trehalose; Water | 2012 |
Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Phosphatidylcholines; Polyethylene Glycols; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2013 |